AZAPROPAZONE IN THE TREATMENT OF ANKYLOSING SPONDYLITIS: A CONTROLLED CLINICAL TRIAL

Abstract
In a controlled clinical trial the effect of azapropazone (900 mg. daily) was compared with placebo in 18 out-patients with ankylosing spondylitis. The trial was of “crossover” design, and results suggest that azapropazone may be of value in the symptomatic management of ankylosing spondylitis. The side-effects of the drug were mild and occurred with similar frequency during both drug and placebo periods.

This publication has 0 references indexed in Scilit: